<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Modifiable risk factors for cardiovascular disease in patients with severe mental illness</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Modifiable risk factors for cardiovascular disease in patients with severe mental illness</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Modifiable risk factors for cardiovascular disease in patients with severe mental illness</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">L Fredrik Jarskog, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rupal Yu, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3200337605"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lifespans in people with severe mental illness (SMI) are reduced by 15 to 25 years compared with the general public [<a href="#rid1">1-3</a>]. Cardiovascular disease (CVD) represents the most common natural cause of excess mortality [<a href="#rid1">1,4,5</a>]. People with schizophrenia, for example, are twice as likely to die from CVD [<a href="#rid6">6-8</a>].</p><p>Modifiable CVD risk factors for CVD include obesity, smoking, diabetes mellitus, hypertension, and dyslipidemia. Concurrent elevation of these risk factors, collectively, is known as metabolic syndrome, which is more common in patients with SMI compared with the general population. The syndrome is also a common side effect of antipsychotic medications, which are used both for psychotic disorders and, with increasing frequency, for nonpsychotic psychiatric disorders  (<a class="graphic graphic_table graphicRef117484" href="/z/d/graphic/117484.html" rel="external">table 1</a>). Patients with SMI with metabolic risk factors often go undiagnosed, untreated or undertreated for these conditions. (See  <a class="medical medical_review" href="/z/d/html/14775.html" rel="external">"Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications"</a>.)</p><p>This topic reviews the epidemiology of individual CVD risk factors, as well as the efficacy and administration of interventions to treat them in patients with SMI. The epidemiology, pathogenesis, and clinical implications of metabolic syndrome in patients with SMI are reviewed separately. Lifestyle interventions for obesity and overweight patients with SMI are also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14775.html" rel="external">"Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications"</a> and  <a class="medical medical_review" href="/z/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness"</a>.)</p><p class="headingAnchor" id="H3915415027"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>This topic describes treatment options for metabolic abnormalities in patients with severe mental illness. Our approach to selecting treatments among these options is described separately. (See  <a class="medical medical_review" href="/z/d/html/117204.html" rel="external">"Approach to managing increased risk for cardiovascular disease in patients with severe mental illness"</a>.)</p><p class="headingAnchor" id="H2264098394"><span class="h1">MONITORING</span></p><p class="headingAnchor" id="H1364320539"><span class="h2">Patients with severe mental illness</span><span class="headingEndMark"> — </span>Patients with severe mental illness (SMI) should be assessed at regular intervals  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 2</a>) for:</p><p class="bulletIndent1"><span class="glyph">●</span>Personal and family history of diabetes, hypertension or cardiovascular disease (annually)</p><p class="bulletIndent1"><span class="glyph">●</span>Smoking, physical activity and diet (quarterly)</p><p class="bulletIndent1"><span class="glyph">●</span>Weight and body mass index (quarterly)</p><p class="bulletIndent1"><span class="glyph">●</span>Blood pressure (quarterly)</p><p class="bulletIndent1"><span class="glyph">●</span>Fasting blood glucose or HbA1c (annually)</p><p class="bulletIndent1"><span class="glyph">●</span>Lipid profile (annually)</p><p></p><p class="headingAnchor" id="H4267550109"><span class="h2">Patients treated with antipsychotics</span><span class="headingEndMark"> — </span>Patients initiating treatment with any antipsychotic medication should be assessed with greater frequency during the first year and then at least annually. A table provides a recommended monitoring schedule  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 2</a>), largely based on a 2004 consensus statement by the American Diabetes Association, the American Psychiatric Association, the American Association of Clinical Endocrinologists, and the North American Association for the Study of Obesity [<a href="#rid9">9</a>]. It is augmented by more recent European guidelines calling for more frequent glucose and lipid monitoring [<a href="#rid10">10</a>], reflecting more prudent clinical care in a population with substantially impaired general physical health and increased mortality rates.</p><p>Monitoring should be tailored to the individual patient. As an example, monitoring should be more frequent if values are abnormal in people receiving chronic antipsychotic therapy.</p><p class="headingAnchor" id="H3322597264"><span class="h1">OVERWEIGHT AND OBESITY</span></p><p class="headingAnchor" id="H550271429"><span class="h2">Definitions</span></p><p class="bulletIndent1"><span class="glyph">●</span>Body mass index (BMI) – A weight-to-height ratio, calculated by dividing one's weight in kilograms by the square of one's height in meters</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overweight – BMI 25 to &lt;30</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obesity – BMI &gt;30</p><p></p><p class="headingAnchor" id="H1946118263"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>The prevalence of obesity among individuals with severe mental illness (SMI) is increased compared with the general population. Higher prevalence rates have been found for several psychiatric disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schizophrenia</strong> – 49.4 percent met criteria for abdominal obesity per metabolic syndrome criteria in a meta-analysis of 77 studies with a total of 25,692 participants [<a href="#rid11">11</a>]. Much of the research evidence informing management of metabolic abnormalities in patients with SMI is based on trials in schizophrenia, a more widely studied group that other SMIs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonpsychotic mood disorders</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bipolar disorder</strong> – The prevalence of abdominal obesity was 48.7 percent in 4573 patients with bipolar disorder in a meta-analysis of 11 studies [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Major depression</strong> – The prevalence of abdominal obesity was 41.6 percent in 3118 patients with major depression in a meta-analysis of four studies [<a href="#rid13">13</a>].</p><p></p><p class="headingAnchor" id="H871881332"><span class="h2">Treatment</span></p><p class="headingAnchor" id="H3660791879"><span class="h3">Lifestyle interventions</span><span class="headingEndMark"> — </span>A comprehensive lifestyle intervention to promote weight loss involves educating and encouraging patients with regard to their nutrition, diet, and physical activity. Interventions have been customized to address the needs of patients with SMI [<a href="#rid14">14</a>]. The components and efficacy of lifestyle interventions for patients with SMI are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness"</a>.)</p><p></p><p>All patients with SMI who have obesity or who are overweight, regardless of the availability of a lifestyle intervention or whether they are receiving other treatment, should receive education and encouragement on their nutrition, diet, and physical activity.</p><p class="headingAnchor" id="H1835270646"><span class="h3">Changes to antipsychotic regimen</span><span class="headingEndMark"> — </span>For many individuals, antipsychotic medication represents a major cause of weight gain. For each individual with antipsychotic associated weight gain, the benefits of medication change need to be weighed against the risks of recurrent psychosis. If clinically appropriate, a dose reduction can be considered, although the evidence for a dose dependent relationship with weight gain for most antipsychotics is limited [<a href="#rid15">15</a>]. Another option is to change the antipsychotic medication to one less likely to cause weight gain  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">table 4</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Lowering the dose of their present antipsychotic regimen – When appropriate, we lower the antipsychotic dose slowly (eg, every one to two months) and in small amounts (eg, 25 percent or less) while monitoring carefully for psychotic symptom exacerbation. We obtain weights at each clinic visit and encourage patients to measure weights at home.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Changing to another antipsychotic regimen with less potential to cause weight gain – Examples include <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> or <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a> [<a href="#rid16">16,17</a>]. In cases where the individual is taking <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> with good clinical effect but is also gaining weight, it is reasonable to offer the fixed-dose combination <a class="drug drug_general" data-topicid="131761" href="/z/d/drug information/131761.html" rel="external">olanzapine-samidorphan</a>. It should be noted that the current evidence base for samidorphan is limited to attenuation of weight gain in people who are starting olanzapine as opposed to producing weight loss in people who have already gained weight on olanzapine [<a href="#rid18">18</a>].</p><p></p><p><a class="drug drug_general" data-topicid="131761" href="/z/d/drug information/131761.html" rel="external">Olanzapine-samidorphan</a> is a fixed-dose combination of the second-generation antipsychotic <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> with samidorphan, an opioid antagonist found to attenuate olanzapine-induced weight gain [<a href="#rid19">19</a>]. A randomized trial of 561 patients with schizophrenia compared the combination of olanzapine-samidorphan with olanzapine only for 24 weeks [<a href="#rid18">18</a>]. At the end of the study, the mean increase in body weight was lower in the olanzapine-samidorphan group (3.2 versus 5.1 kg in the olanzapine group). Additionally, subjects in the olanzapine-samidorphan group were less likely to gain 10 percent or more of their body weight (odds ratio 0.5, 95% CI 0.31-0.80) and had smaller increases in waist circumference (a proxy for central fat accumulation and risk of greater cardiovascular disease and diabetes). However, samidorphan was not associated with any improvements in laboratory-based metabolic endpoints including cholesterol, triglyceride, glucose, HbA1C, or insulin levels. Treatment with combined olanzapine-samidorphan resulted in similar improvements in symptoms of schizophrenia compared to olanzapine only group with similar adverse effects including somnolence, increased appetite, and dry mouth.</p><p>Further discussion of how to make changes to antipsychotic regimen due to side effects can be found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Implementation of medication changes'</a>.)</p><p class="headingAnchor" id="H2112779622"><span class="h3">Adjunctive medications</span><span class="headingEndMark"> — </span>Pharmacologic options for weight loss in patients with SMI are limited. Adjunctive medications to reduce antipsychotic-induced weight gain can be used concurrently with, or provide an alternative to behavioral modifications for patients who are not motivated for change. Several medications without a US Food and Drug Administration (FDA) indication for weight loss have shown efficacy for weight loss in clinical trials in patients with SMI with antipsychotic-associated weight gain:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metformin</strong> – A 2014 meta-analysis of 10 clinical trials with a total of 757 patients found <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> to be an efficacious treatment for weight loss, with a mean difference in weight reduction favoring metformin compared with placebo of 3.17 kg (95% CI -4.44 to -1.90 kg).</p><p></p><p class="bulletIndent1">As an example, in the largest clinical trial of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> for weight loss in this population, 148 nondiabetic outpatients with schizophrenia or schizoaffective disorder (BMI &gt;27) were randomized to 16 weeks of metformin, titrated up to 2000 mg per day, or placebo [<a href="#rid20">20</a>]. All subjects also received weekly diet and exercise counseling during the study. Over 16 weeks, metformin demonstrated a mean weight reduction compared with placebo showed a weight change of (-3.0 versus 1.0 kg). Metformin was also associated with significant improvements in triglycerides and hemoglobin A1c. Metformin was well tolerated, with only diarrhea reported more frequently for metformin than for placebo.</p><p></p><p class="bulletIndent1">Preventative use of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> is under investigation; it may be moderately effective in preventing weight gain in antipsychotic-naïve individuals starting an antipsychotic. A clinical trial randomly assigned 40 nonobese patients with first-episode schizophrenia either to <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (15 mg/day) plus metformin (750 mg per day) or olanzapine (15 mg/day) plus placebo [<a href="#rid21">21</a>]. After 12 weeks, the metformin group experienced a lower mean weight gain compared with the placebo group (1.9 versus 6.9 kg).</p><p></p><p class="bulletIndent1">Common side effects of <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> include nausea, vomiting, diarrhea and abdominal discomfort. Infrequently, metformin is associated with headaches, myalgia, weakness, and low vitamin B12 levels. Rarely, metformin can produce hypoglycemia, but normally only in the setting of serious malnutrition or alcohol use disorder. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a> is not recommended for use in patients with:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congestive heart failure or other serious cardiac disease</p><p class="bulletIndent2"><span class="glyph">•</span>Serious kidney disease (estimated glomerular filtration rate [eGFR], &lt;45 mL/min/1.73 m<sup>2</sup>)</p><p class="bulletIndent2"><span class="glyph">•</span>Serious liver disease (use caution with liver function tests &gt;3 times normal)</p><p class="bulletIndent2"><span class="glyph">•</span>Metabolic acidosis</p><p class="bulletIndent2"><span class="glyph">•</span>Alcohol use disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Recent use of iodinated contrast material</p><p class="bulletIndent2"><span class="glyph">•</span>Pregnancy</p><p></p><p class="bulletIndent1">Prior to prescribing <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain medical history to rule out serious heart, kidney, and liver disease, as well as alcohol use disorder (moderate alcohol use is safe).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain eGFR, liver function panel, serum bicarbonate, and complete blood count. In patients with anemia, obtain vitamin B12 level, supplement as needed.</p><p></p><p class="bulletIndent1">Dosing/titration</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Begin <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> 500 mg every morning for one week, then increase to 500 mg twice daily for one week.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase by 500 mg every week, as tolerated, up to 1000 mg twice daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If gastrointestinal symptoms emerge, hold titration (or hold dose) until side effect subsides, then restart at last tolerated dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If gastrointestinal symptoms persist, try <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> extended-release formulation.</p><p></p><p class="bulletIndent1">Monitoring while taking <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>eGFR at least annually, or every six months if eGFR&lt;60 mL/min/1.73 m<sup>2</sup></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver function tests annually</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Assess alcohol use regularly</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Consider vitamin B12 annually, especially in patients with anemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topiramate</strong> – Although less well studied, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> shows evidence of efficacy for weight loss in patients with SMI with antipsychotic-associated weight gain. A 2016 meta-analysis of seven clinical trials with a total of 327 patients found a mean difference in weight reduction favoring topiramate compared with placebo of 3.17 kg (95% CI -5.55 to -0.73 kg) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">As an example, a clinical trial randomly assigned 66 overweight inpatients with schizophrenia to <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> (200 mg/day or 100 mg/day), or placebo [<a href="#rid23">23</a>]. After 12 weeks in the 53 patients completing the trial, weight reduction was greater among patients treated with 200 mg/day or 100 mg/day of topiramate compared with placebo (-5.35 or -1.68 versus -0.3 kg). Paresthesia was the only side effect more common in the active treatment groups compared with placebo. A limitation of the trial was that intent to treat data were not presented.</p><p></p><p class="bulletIndent1">Common dose-dependent side effects of <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> in nonpsychiatric populations include paresthesias, sedation, dizziness, and memory difficulties. Rare but serious side effects include nephrolithiasis, secondary angle closure glaucoma, metabolic acidosis, and hyperammonemia [<a href="#rid24">24</a>]. In our experience, slow titration and moderate dosing generally has led to efficacy and tolerable side effects, although paresthesias may occur in as many as 30 percent of patients at topiramate 200 mg per day.</p><p></p><p class="bulletIndent1">Prior to prescribing <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain medical history to rule out serious kidney and liver disease, and rule out history of glaucoma and nephrolithiasis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain eGFR, liver function panel, serum bicarbonate. For eGFR &lt;70 mL/min/1.73 m<sup>2</sup>, reduce target dose of <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> by 50 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Concomitant <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">valproate</a> not recommended due to increased risk of hyperammonemia.</p><p></p><p class="bulletIndent1">Suggested dosing/titration:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Begin <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> 25 mg nightly at bedtime for week 1, then increase to 50 mg nightly at bedtime for week 2.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase to <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a> 50 mg twice daily for week 3, then increase by 50 mg per week, as tolerated, up to 100 mg twice daily.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Can increase or decrease by 25 mg increments if tolerability problems emerge.</p><p></p><p class="bulletIndent1">Monitoring while taking <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>eGFR, liver function panel, and serum bicarbonate three months after starting therapy, then every six months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If mild metabolic acidosis develops, lower dose of <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>. For moderate metabolic acidosis or for significant liver enzyme elevation, topiramate should be discontinued, and further assessment by primary care clinician or internist is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aripiprazole</strong> – Clinical trials have found antipsychotic-associated weight gain in patients treated with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> to be reduced by treatment with adjunctive <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> [<a href="#rid25">25</a>]. A meta-analysis of three clinical trials with a total of 266 patients found a mean difference in weight reduction favoring aripiprazole compared with placebo of 2.13 kg (95% CI -2.87 to -1.39) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">In a meta-analysis of three clinical trials with 260 patients with schizophrenia with antipsychotic-induced weight gain, adjunct <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> reduced patient body weight compared with placebo (mean difference = -2.13 kg [95% CI -2.87 to -1.39 kg]) [<a href="#rid25">25</a>]. As an example, in the largest trial to date, 207 people with schizophrenia taking stable doses of <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> and who had gained at least 2.5 kg with clozapine were randomized to 16 weeks of aripiprazole 5 to 15 mg/day (dosed flexibly, mean dose = 11 mg/day) or placebo [<a href="#rid26">26</a>]. Weight change was greater with aripiprazole compared with placebo (-2.53 versus -0.38 kg), with a between-group difference of -2.15 kg. Total cholesterol and low density lipoprotein levels also improved with aripiprazole.</p><p></p><p class="bulletIndent1">Side effects of <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> that have been reported when taken together with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> include nausea, anxiety, and akathisia [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1">Begin <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> 5 mg nightly at bedtime for week 1. Increase in 5 mg increments per week up to 15 mg nightly, as tolerated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liraglutide</strong> – <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">Liraglutide</a> is a glucagon-like peptide-1 agonist that was approved for weight loss by the FDA in 2014. Emerging data indicates liraglutide may be safe and effective for weight loss in overweight and patients with obesity and SMI. In a clinical trial, 103 overweight or individuals with obesity, schizophrenia spectrum disorders, prediabetes taking <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> were randomly assigned to receive liraglutide or placebo for 16 weeks [<a href="#rid27">27</a>]. Patients receiving liraglutide lost weight, while patients receiving placebo had an average weight gain (-4.7 versus 0.5 kg).</p><p></p><p class="bulletIndent1">Common side effects include nausea, abdominal discomfort, and diarrhea. Rarely, <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> has been associated with hypoglycemia, pancreatitis, cholelithiasis, and cholecystitis. Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2.</p><p></p><p class="bulletIndent1">Begin <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> 0.6 mg subcutaneously per day for week 1. Increase to 1.2 mg per day for week 2 and then to a final target dose of 1.8 mg per day starting week 3, as tolerated. In our experience, the titration may need to be slowed due to gastrointestinal side effects.</p><p></p><p class="headingAnchor" id="H2110932809"><span class="h1">DIABETES</span></p><p class="headingAnchor" id="H2377348173"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>People with severe mental illness (SMI) have a higher prevalence of diabetes compared with the general population [<a href="#rid28">28</a>]. Studies of people with schizophrenia, bipolar disorder, and schizoaffective disorder have found a prevalence of type 2 diabetes two- to threefold higher compared with the general population [<a href="#rid29">29</a>]. The role of type 2 diabetes in the development of cardiovascular disease is described separately. (See  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease", section on 'Diabetes mellitus'</a>.)</p><p>Antipsychotic medication use contributes to the development of diabetes. As an example, a population-based study in Taiwan examined cohorts of patients with newly diagnosed schizophrenia prescribed either a first-generation antipsychotic (FGA) or a second-generation antipsychotic (SGA) medication beginning between 1997 and 2000. FGA (1631 patients) and SGA (224 patients) cohorts were followed until 2008 and compared with age- and sex-matched, non-schizophrenia controls. FGA treatment was associated with developing diabetes (hazard ratio 1.32, 95% CI 1.01-1.755), an association that was greater in patients treated with SGA (hazard ratio 1.82, 95% CI 1.30-2.55) [<a href="#rid30">30</a>].</p><p>A 2012 systematic review found no difference between FGA and SGA in the risk of developing metabolic syndrome or diabetes; however, the strength of evidence was insufficient for a conclusive determination [<a href="#rid31">31</a>].</p><p>Further increasing the burden of diabetes in people with mental illness is that they receive less intensive medical care leading to poorer diabetes control and increased risks of complications [<a href="#rid32">32-34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a national, cross-sectional study of 313,586 veterans with diabetes in the United States, those with psychiatric disorders were less likely to have been evaluated for hemoglobin (HbA1c), low density lipoproteins, glycemic or lipemic control, or ophthalmic complications [<a href="#rid32">32</a>]. A trend towards poorer diabetes control was seen in patients with increasing number of mental health conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective matched cohort study derived from administrative data of over 5000 individuals in Ontario, Canada, found that individuals with schizophrenia were more likely to have had an emergency department visit or hospitalization for hypoglycemia, hyperglycemia, or diabetes-related infection (21 versus 14 percent) [<a href="#rid34">34</a>]. Such complications can largely be managed or prevented with adequate monitoring, resources, and patient support.</p><p></p><p class="headingAnchor" id="H74705142"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Once feasible changes to patients’ antipsychotic regimens are made, subsequent treatment options for type 2 diabetes are the same for patients whether or not she or he takes an antipsychotic or has an SMI. Initial management of hyperglycemia in adults with type 2 diabetes consists of patient education including nutrition and self-management skills and pharmacotherapy. (See <a class="local">'Changes to antipsychotic regimen'</a> above and  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p>A lifestyle intervention developed to address cardiovascular disease risk factors in patients with SMI, diabetes, and excess weight has been developed and tested. A randomized clinical trial supports the efficacy of the intensive, multimodal lifestyle intervention for cardiovascular risk factors in middle-aged and older outpatients with schizophrenia and type 2 diabetes mellitus outpatients [<a href="#rid35">35</a>].</p><p>The trial randomly assigned 62 outpatients with the co-occurring conditions aged 40 and over to receive the intervention or usual care (along with pamphlets from the American Diabetes Association). The intervention group received weekly 90-minute sessions providing education on diet, exercise, and other diabetes self-care activities. Concrete behavioral change strategies were utilized, including weekly weighing, pedometers, healthy food samplings, and positive reinforcements for group attendance and behavioral change.</p><p>After 24 weeks, the intervention group had a superior mean weight change compared with usual care (-2.3 versus 3.1 kg). The intervention group also had superior outcomes on body mass index, waist circumference, triglycerides, and diabetes knowledge. At six-month follow-up, improvements in all but diabetes knowledge were maintained [<a href="#rid36">36</a>].</p><p>While they have been tested in clinical trials, diabetes intervention programs designed specifically for patients with SMI are difficult to find. The Behavioral Health Home model has shown progress in reducing chronic disease burden as well as health care costs, but these programs are only available to publicly insured patients in some states in the United States [<a href="#rid37">37,38</a>].</p><p>Care should be coordinated between mental health providers (of both medication and psychotherapy), the primary care provider or endocrinologist and care management/social work (if involved). For patients with SMI who participate in treatment of their mental illness but cannot or choose not to attend general medical visits, the psychiatrist (if comfortable doing so) should initiate treatment for diabetes in an effort to bridge care and reduce morbidity. (See  <a class="medical medical_review" href="/z/d/html/117204.html" rel="external">"Approach to managing increased risk for cardiovascular disease in patients with severe mental illness", section on 'Site of treatment'</a>.)</p><p>Monitoring of patients with SMI with type 2 diabetes includes a fasting blood glucose or HbA1c every three months (for patients not at goal; otherwise and every six months) and a foot exam, retinopathy screening, and urine microalbuminuria annually, along with monitoring of other metabolic abnormalities  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 2</a>). (See <a class="local">'Monitoring'</a> above.)</p><p class="headingAnchor" id="H3670739100"><span class="h1">HYPERTENSION</span></p><p class="headingAnchor" id="H483434461"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Approximately 29 percent of the United States adult population has hypertension [<a href="#rid39">39</a>]. Hypertension is two to three times more frequent among people with schizophrenia and bipolar disorder compared with the general population [<a href="#rid40">40</a>].</p><p>Disparities in the identification and treatment of hypertension have been observed between patients with severe mental illness (SMI) and the general population [<a href="#rid41">41,42</a>]. As an example, a naturalistic cohort study of 542 outpatients with SMI, found that 42 percent were identified as having a blood pressure of &gt;140/90; 74 percent of these individuals were not treated with antihypertensive medication [<a href="#rid41">41</a>]. Thirty-seven percent of those with hypertension who were reassessed at one year were still hypertensive.</p><p class="headingAnchor" id="H284630467"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>There are no randomized clinical trials examining interventions to lower blood pressure as a primary outcome among patients with SMI [<a href="#rid43">43</a>]. Treatment of hypertension for patients with SMI is the same as for the general population, which is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p>Considerations informing the diagnosis and treatment of hypertension in patients with SMI include:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are acutely psychotic may present with elevated blood pressure which normalizes after treatment of their mental illness. In such patients, it is prudent to monitor blood pressure closely over time and check out-of-office readings if possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with SMI are more vulnerable to side effects and drug-drug interactions due to receiving multiple medications. As an example, angiotensin converting enzyme inhibitors/angiotensin receptor blockers are relatively contraindicated for people taking <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a> due to risk of lithium toxicity [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although beta blockers are not recommended as first-line agents for the general population, people with antipsychotic-associated tachycardia (as seen with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>) and hypertension may benefit from adding a beta blocker first to address both conditions.</p><p></p><p>Monitor the blood pressure of patients with SMI with high blood pressure at three month intervals. Counseling on lifestyle changes and assessing for medication adherence and side effects should be a part of every visit.</p><p class="headingAnchor" id="H2638282716"><span class="h1">DYSLIPIDEMIA</span></p><p class="headingAnchor" id="H1855225124"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Dyslipidemia, the development of increased cholesterol or triglyceride levels or reduced high density lipoprotein, is an easily recognized and treatable cardiovascular risk factor among people with severe mental illness (SMI).</p><p>The relationship between total cholesterol and elevated low density lipoprotein and risk of cardiovascular disease (CVD) is well established [<a href="#rid45">45</a>]. The role of hypertriglyceridemia as a cardiovascular risk factor is increasingly being recognized. (See  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.)</p><p>It is estimated that 25 to 69 percent of people with schizophrenia have some degree of dyslipidemia [<a href="#rid40">40</a>]. It is unclear how much this increased risk is attributable to antipsychotic medication compared with behavioral risk factors. While all antipsychotic medications increase the risk of unfavorable changes in cholesterol, certain second-generation antipsychotics, such as <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a> and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, are particularly associated with increases in total and low density lipoprotein cholesterol [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H590904208"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>There are no clinical trials of the efficacy of treatment for dyslipidemia as a primary outcome in patients with SMI. Dyslipidemia treatment in patients with SMI is the same as in the general population, which is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p>Monitoring of patients with SMI for dyslipidemia is described in a table  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 2</a>) and reviewed below. Nonfasting lipid profiles are more convenient for the patient and yield low density lipoprotein-cholesterol values of similar prognostic value [<a href="#rid47">47</a>]. A fasting lipid profile is warranted if the non-fasting results show hypertriglyceridemia. Use of lipid profile results in a CVD risk assessment to calculate patient risk of CVD is reviewed separately. (See <a class="local">'Monitoring'</a> above and  <a class="medical medical_review" href="/z/d/html/1546.html" rel="external">"Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults: Our approach"</a>.)</p><p>Lower lipid thresholds for starting statin treatment should be considered for patients with SMI compared with the general population, particularly for younger patients with SMI. For patients with SMI ages 21 to 39, we recommend calculating a 10-year CVD risk as if they were age 40. If the 10-year CVD risk is &gt;7.5 percent, our recommendations are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Emphasize and offer support for behavioral modifications (improved nutrition and increased physical activity). (See  <a class="medical medical_review" href="/z/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Control blood pressure, either by lifestyle changes or medication. (See <a class="local">'Hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encourage smoking cessation and offer pharmacotherapy. (See <a class="local">'Tobacco smoking'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consider initiation of a moderate-intensity statin medication. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p></p><p>We recognize this approach to statin initiation in patients with SMI under age 40 is not evidence based. However, we believe that the potential long-term benefits of this strategy outweigh the potential risks in efforts to reduce the disproportionate burden of poor CVD outcomes in this population.</p><p class="headingAnchor" id="H3784058011"><span class="h1">TOBACCO SMOKING</span></p><p class="headingAnchor" id="H310223166"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span>Individuals with severe mental illness (SMI) have a high prevalence of cigarette smoking (30 to 62 percent) compared with the general population in the United States. The prevalence of smoking in people with bipolar disorder and major depression is somewhat lower than for schizophrenia but still substantially elevated compared with the general population [<a href="#rid48">48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>General population in the United States</strong> – 16.8 percent [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schizophrenia</strong> – 62 percent of people with schizophrenia were current smokers in a meta-analysis of studies from 20 countries [<a href="#rid50">50</a>]. Subjects with schizophrenia were five times more likely to smoke compared with subjects from the general population. Smoking rates were higher in male subjects with schizophrenia compared with females (71 versus 44 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bipolar disorder</strong> – 45 percent of people with bipolar disorder were current smokers in 51 studies comprising 41,710 people.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major depression</strong> – 30 percent of people with major depression were current smokers in 18 studies with 105,856 people.</p><p></p><p class="headingAnchor" id="H1160502222"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>The basis for high smoking rates in patients with SMI is multifactorial and likely includes complex interactions between disease-specific genetic and neurobiological factors, in addition to psychosocial and treatment-related factors. As an example, genetic linkage analysis has localized the P50 auditory sensory gating deficit in schizophrenia to chromosome 15q13-14, which is the site of the alpha-7 nicotinic acetylcholine receptor subunit. It has been hypothesized that increased rates of smoking in people with schizophrenia is due in part to efforts to activate the alpha-7 subunit, which has inherently low affinity to <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> and which also demonstrates reduced cortical expression in schizophrenia [<a href="#rid51">51</a>].</p><p>From a psychosocial perspective, epidemiologic studies show substantially higher rates of smoking in people with low socioeconomic status and in those with a disability [<a href="#rid52">52</a>]; people with serious mental illness often meet criteria for both categories. Smoking to relieve side effects associated with antipsychotic medications such as sedation and neuroleptic-induced dysphoria has long been considered an attempt at self-medication [<a href="#rid53">53</a>]. <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">Clozapine</a> has been found to reduce smoking in people with schizophrenia, thought to be related to its ability to enhance acetylcholine release in hippocampus and increase P50 sensory gating [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H2375407939"><span class="h2">Treatments</span></p><p class="headingAnchor" id="H3685384843"><span class="h3">Bupropion</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a>, compared with placebo, has been found to be efficacious in increasing smoking cessation in patients with schizophrenia, bipolar disorder, and depression. (See <a class="local">'Nicotine replacement treatment'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schizophrenia</strong> – A 2013 Cochrane meta-analysis of five randomized clinical trials with 214 patients with schizophrenia found <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> with or without <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT) to be efficacious for smoking cessation [<a href="#rid54">54</a>]. At six months, bupropion was associated with nearly three times greater likelihood of continued abstinence compared with placebo. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2007 trial randomly assigned 51 patients with schizophrenia who smoked at least 10 cigarettes per day to 12 weeks of <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> (150 mg twice daily) or to placebo. All subjects also received NRT and cognitive-behavioral therapy for smoking cessation. Participants who received bupropion, compared with placebo, had a greater rate of smoking reduction at week 12 (60 versus 31 percent) and week 24 [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A 2016 trial, which found <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> sustained-release (SR) to be efficacious compared with placebo in a larger sample of patients with various SMI diagnoses, found a nonsignificant trend for the medication in a secondary analysis of 98 patients with psychotic disorders [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bipolar disorder and depression</strong> – While earlier, smaller trials showed equivocal results for <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> in patients with bipolar disorder and depression [<a href="#rid57">57,58</a>], a secondary analysis of a large 2016 randomized trial that included 1455 patients with major depression or bipolar disorder found bupropion SR to be efficacious [<a href="#rid56">56</a>]. After 24 weeks, the continuous abstinence rate was greater for bupropion compared with placebo (odds ratio 1.75, 95% CI 1.27-2.41) [<a href="#rid56">56</a>].</p><p></p><p>Common side effects for <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> include headache, dry mouth, and insomnia. Bupropion can increase blood pressure, which should be monitored carefully after initiation, especially in a patient with a history of hypertension. Bupropion has been associated with a dose-dependent increased risk of seizure (0.1 percent at 300 mg per day) and should not be used in patients with a history of seizure.</p><p><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> SR can be started at 150 mg once daily for three days (longer if poorly tolerated), then increased to 150 mg twice daily for the remainder of the treatment period, 8 to 12 weeks. The dose should not exceed 300 mg total per day. Patients are advised to start bupropion treatment one to two weeks prior to a target smoking quit date. The twice daily dosing interval should be at least eight hours to reduce seizure risk. The second dose can be taken earlier in the evening to avoid insomnia.</p><p class="headingAnchor" id="H4114839988"><span class="h3">Varenicline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a>, compared with placebo, has been found to be efficacious in smoking cessation in patients with schizophrenia, bipolar disorder, and depression:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schizophrenia </strong>– The 2013 meta-analysis included two randomized clinical trials showing <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> to be efficacious and safe in 137 patients with schizophrenia [<a href="#rid54">54</a>]. Participants who took varenicline were nearly five times as likely to abstain from smoking at the end of treatment compared with placebo.</p><p></p><p class="bulletIndent1">As an example, a trial randomly assigned 127 smokers (&gt;15 cigarettes per day) with schizophrenia or schizoaffective disorder to 12 weeks of <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> (1 mg twice daily) or placebo [<a href="#rid59">59</a>]. At 12 weeks, patients in the varenicline group were more likely to meet abstinence criteria compared with the placebo group (19 versus 4.7 percent). Varenicline was generally well tolerated, with nausea, headache, and insomnia reported more frequently for varenicline compared with placebo. There was no evidence that psychiatric symptom side effects were more frequent or severe for varenicline compared with placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bipolar disorder and depression</strong> – Multiple randomized clinical trials have found <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> to be largely efficacious for smoking cessation in patients with bipolar disorder [<a href="#rid56">56,60-62</a>] and major depression [<a href="#rid56">56,60,63</a>]. As an example, the 2016 trial randomly assigned 734 patients with major depression and bipolar disorder to 12 weeks of varenicline (1 mg twice daily) or placebo. Patients assigned to varenicline were more likely to achieve continuous abstinence during the trial compared with placebo (odds ratio 2.28, 95% CI 1.67-3.11) [<a href="#rid56">56</a>].</p><p></p><p>Common side effects include nausea, restlessness, and abnormal/vivid dreams. (See <a class="local">'Safety'</a> below.)</p><p><a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">Varenicline</a> can be started at 0.5 mg once daily for days 1 to 3, then increased to 0.5 mg twice daily for days 4 to 7, then increased to 1 mg twice daily for the remainder of treatment, 12 weeks total. Patients are advised to start varenicline one week prior to a target smoking quit date.</p><p>For patients who are unwilling or unable to abruptly quit smoking, they should target 50 percent smoking reduction by four weeks after starting <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, then reduce smoking by another 50 percent by eight weeks with a goal of stopping smoking by 12 weeks. For this group, varenicline should be continued for an additional 12 weeks.</p><p class="headingAnchor" id="H66784892"><span class="h3">Nicotine replacement treatment</span><span class="headingEndMark"> — </span>Overall, the balance of evidence suggests that NRT is efficacious for smoking cessation patients with mood disorders, but unclear in patients with psychotic disorders. Seven small trials using heterogeneous study designs to test NRT for patients with SMI were negative for the primary outcome of smoking cessation [<a href="#rid54">54,58</a>].</p><p>A large 2016 clinical trial randomly assigned 2051 patients with mood, anxiety, and psychotic disorders to receive NRT (21 mg per day, transdermal patch) or placebo [<a href="#rid60">60</a>]. Patients assigned to NRT were more likely to achieve continuous abstinence during the trial compared with placebo (odds ratio 1.65, 95% CI 1.24-2.20). Subgroup analyses found that the 721 patients with mood disorders were more likely to achieve continuous abstinence on NRT compared with placebo, but no difference was seen in the 99 patients with psychotic disorders [<a href="#rid56">56</a>].</p><p>In our clinical experience, NRT has contributed to successful smoking cessation in motivated patients with schizophrenia spectrum disorders.</p><p>Common side effects of NRT include abnormal or vivid dreams and insomnia. Long-acting NRT may need to be removed at night to minimize these side effects. Some side effects such as tachycardia, nausea and dizziness may occur because the dose of NRT is too high for the patient. Ensure that the patient’s prior cigarette use is carefully assessed in order to find their optimal NRT dose.</p><p>Also consider symptoms of <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> withdrawal in patients for whom nicotine is underdosed. Common side effects of withdrawal include insomnia, restlessness, irritability, and cravings. Consider the use of short-acting NRT in combination with long-acting NRT for patients who were heavy smokers and experience severe withdrawal.</p><p>Dosing and administration of NRT in patients with SMI follows guidelines for NRT treatment the general population. These are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults", section on 'Administration'</a>.)</p><p class="headingAnchor" id="H1447890075"><span class="h3">Safety</span><span class="headingEndMark"> — </span>Concern that <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> might be associated with exacerbation of psychiatric symptoms in the treatment of patients with psychiatric disorders have not been supported by subsequent analyses. The US Food and Drug Administration issued a black box warning for varenicline and bupropion in 2009 for risks of depression and suicidal thoughts/behavior based on analysis of postmarketing surveillance data. Subsequent study has not supported the associations [<a href="#rid60">60,64,65</a>], leading to the withdrawal of the warning in 2016 [<a href="#rid66">66</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A clinical trial of 8144 smokers motivated to quit, half of whom had stable psychiatric disorders (eg, major depressive, bipolar, anxiety or psychotic disorders) compared treatment with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>, <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, NRT, or placebo [<a href="#rid60">60</a>]. After 12 weeks, rates of neuropsychiatric adverse events did not differ by treatment assignment. Patients with psychiatric comorbidity had a higher rate of neuropsychiatric symptoms compared with patients without the comorbidity, but rates were low for both groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and meta-analysis of 39 randomized trials including over 10,000 participants with and without psychiatric illness also found that <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> did not increase the risk of suicide or suicide attempts, suicidal ideation, depression, aggression, or death compared with placebo [<a href="#rid65">65</a>].</p><p></p><p class="headingAnchor" id="H2107382012"><span class="h2">Psychosocial interventions</span><span class="headingEndMark"> — </span>In contrast to clinical trials in the general population, clinical trials in patients with SMI do not consistently demonstrate efficacy for any particular psychosocial intervention for smoking cessation [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a>.)</p><p>As an example, a trial randomly assigned 45 patients with schizophrenia or schizoaffective disorder to 10 weeks of specialized smoking cessation group therapy or a standard manualized behavioral group therapy [<a href="#rid67">67</a>]. All subjects received treatment with transdermal <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> patch 21 mg per day. The patients assigned to the specialized group therapy showed a trend toward a small advantage in smoking abstinence in the last four weeks of treatment (32.1 versus 23.5 percent) compared with the American Lung Association group. At six-month follow-up, however, smoking abstinence was higher in the American Lung Association group (17.6 versus 10.7 percent) compared with the specialized group therapy.</p><p class="headingAnchor" id="H813990675"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic syndrome is a constellation of risk factors for cardiovascular disease including abdominal obesity, insulin resistance, dyslipidemia (elevated triglycerides levels and low density lipoprotein-cholesterol), and hypertension. Metabolic syndrome is more common in patients with severe mental illness (SMI) and is also a side effect of many antipsychotic medications. (See  <a class="medical medical_review" href="/z/d/html/14775.html" rel="external">"Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>This topic reviews treatment options for metabolic abnormalities in patients with SMI. Our approach to selecting treatment among these options is described separately. (See  <a class="medical medical_review" href="/z/d/html/117204.html" rel="external">"Approach to managing increased risk for cardiovascular disease in patients with severe mental illness"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with SMI, at minimum, should be assessed annually for their personal and family history of diabetes, hypertension, and cardiovascular disease; fasting blood glucose or HbA1c; and lipid profile  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 2</a>). Their smoking status, physical activity and diet, body weight, and blood pressure should be assessed quarterly. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients initiating treatment with an antipsychotic medication should be assessed with greater frequency during the first year  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 2</a>) and then at least annually, but the frequency of monitoring should be tailored to the individual patient. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Estimates of the prevalence of obesity in patients with SMI in the United States range from approximately 28 percent in patients with major depression or bipolar disorder to nearly 50 percent of patients with schizophrenia. (See <a class="local">'Overweight and Obesity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">Metformin</a>, <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">topiramate</a>, and adjunctive <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> have shown efficacy in treating antipsychotic-induced weight gain in patients treated with antipsychotic drugs. Lifestyle interventions for obesity and overweight patients have been customized for the SMI population, and are reviewed separately. (See <a class="local">'Adjunctive medications'</a> above and  <a class="medical medical_review" href="/z/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with SMI have a higher prevalence of tobacco smoking compared with the general population in the United States and internationally. (See <a class="local">'Tobacco smoking'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> and <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> have been found to be efficacious and safe in smoking cessation treatment in patients with schizophrenia (or psychotic disorders), bipolar disorder and depression (or mood disorders). <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">Nicotine</a> replacement therapy has been found to be efficacious in patients with bipolar disorder and depression (or mood disorders), but not in patients with schizophrenia (or psychotic disorders). (See <a class="local">'Tobacco smoking'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Studies of people with schizophrenia, bipolar disorder, and schizoaffective disorder have found prevalences of type 2 diabetes two- to threefold higher compared with the general population. (See <a class="local">'Diabetes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Educational and self-management programs, and lifestyle interventions for diabetes care, have been customized for the SMI population; their availability varies widely. Initial management of hyperglycemia in patients with SMI with type 2 diabetes, including glycemic control and pharmacotherapy are the same as in the general population; these are reviewed separately. (See <a class="local">'Diabetes'</a> above and  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension is two to three times more frequent among people with schizophrenia and bipolar disorder compared with the general population. (See <a class="local">'Hypertension'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of dyslipidemia has been found to be higher in patients with schizophrenia compared with the general population. (See <a class="local">'Dyslipidemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment of hypertension and dyslipidemia in patients with SMI are generally the same as in the general population and are reviewed separately. However, treatment for dyslipidemia is recommended to be started at a lower threshold of abnormal lipid values compared with the general population. (See <a class="local">'Hypertension'</a> above and <a class="local">'Dyslipidemia'</a> above and  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a> and  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150:1115.</a></li><li><a class="nounderline abstract_t">Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620.</a></li><li><a class="nounderline abstract_t">Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014; 10:425.</a></li><li><a class="nounderline abstract_t">Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2010; 24:17.</a></li><li><a class="nounderline abstract_t">Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45:21.</a></li><li><a class="nounderline abstract_t">Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212.</a></li><li><a class="nounderline abstract_t">Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013; 368:1594.</a></li><li><a class="nounderline abstract_t">Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66:1116.</a></li><li><a class="nounderline abstract_t">American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267.</a></li><li><a class="nounderline abstract_t">De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2011; 8:114.</a></li><li><a class="nounderline abstract_t">Mitchell AJ, Vancampfort D, Sweers K, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull 2013; 39:306.</a></li><li><a class="nounderline abstract_t">Vancampfort D, Vansteelandt K, Correll CU, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013; 170:265.</a></li><li><a class="nounderline abstract_t">Vancampfort D, Correll CU, Wampers M, et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med 2014; 44:2017.</a></li><li><a class="nounderline abstract_t">McIntyre RS, Kwan ATH, Rosenblat JD, et al. Psychotropic Drug-Related Weight Gain and Its Treatment. Am J Psychiatry 2024; 181:26.</a></li><li><a class="nounderline abstract_t">Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009; 70:1041.</a></li><li><a class="nounderline abstract_t">Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168:947.</a></li><li><a class="nounderline abstract_t">Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003; 23:595.</a></li><li><a class="nounderline abstract_t">Correll CU, Newcomer JW, Silverman B, et al. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. Am J Psychiatry 2020; 177:1168.</a></li><li><a class="nounderline abstract_t">Kahn RS, Kane JM, Correll CU, et al. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study. J Clin Psychiatry 2023; 84.</a></li><li><a class="nounderline abstract_t">Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013; 170:1032.</a></li><li><a class="nounderline abstract_t">Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165:352.</a></li><li><a class="nounderline abstract_t">Correll CU, Maayan L, Kane J, et al. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials. J Clin Psychiatry 2016; 77:e746.</a></li><li><a class="nounderline abstract_t">Ko YH, Joe SH, Jung IK, Kim SH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clin Neuropharmacol 2005; 28:169.</a></li><li><a class="nounderline abstract_t">Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11:722.</a></li><li><a class="nounderline abstract_t">Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014; 40:1385.</a></li><li><a class="nounderline abstract_t">Fleischhacker WW, Heikkinen ME, Olié JP, et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13:1115.</a></li><li><a class="nounderline abstract_t">Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2017; 74:719.</a></li><li><a class="nounderline abstract_t">Poulos J, Normand ST, Zelevinsky K, et al. Antipsychotics and the risk of diabetes and death among adults with serious mental illnesses. Psychol Med 2023; 53:7677.</a></li><li><a class="nounderline abstract_t">Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14:119.</a></li><li><a class="nounderline abstract_t">Liao CH, Chang CS, Wei WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res 2011; 126:110.</a></li><li><a class="nounderline abstract_t">Hartling L, Abou-Setta AM, Dursun S, et al. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med 2012; 157:498.</a></li><li><a class="nounderline abstract_t">Frayne SM, Halanych JH, Miller DR, et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med 2005; 165:2631.</a></li><li><a class="nounderline abstract_t">Goldberg RW, Kreyenbuhl JA, Medoff DR, et al. Quality of diabetes care among adults with serious mental illness. Psychiatr Serv 2007; 58:536.</a></li><li><a class="nounderline abstract_t">Becker T, Hux J. Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada. Diabetes Care 2011; 34:398.</a></li><li><a class="nounderline abstract_t">McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial. Schizophr Res 2006; 86:36.</a></li><li><a class="nounderline abstract_t">McKibbin CL, Golshan S, Griver K, et al. A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis. Schizophr Res 2010; 121:203.</a></li><li class="breakAll">https://www.integration.samhsa.gov/clinical-practice/CIHS_Health_Homes_Core_Clinical_Features.pdf (Accessed on May 10, 2018).</li><li><a class="nounderline abstract_t">Druss BG, von Esenwein SA, Glick GE, et al. Randomized Trial of an Integrated Behavioral Health Home: The Health Outcomes Management and Evaluation (HOME) Study. Am J Psychiatry 2017; 174:246.</a></li><li><a class="nounderline abstract_t">Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief 2013; :1.</a></li><li><a class="nounderline abstract_t">DE Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10:52.</a></li><li><a class="nounderline abstract_t">Steylen PM, van der Heijden FM, Kok HD, et al. Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment. Int J Psychiatry Clin Pract 2013; 17:125.</a></li><li><a class="nounderline abstract_t">Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86:15.</a></li><li><a class="nounderline abstract_t">McGinty EE, Baller J, Azrin ST, et al. Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review. Schizophr Bull 2016; 42:96.</a></li><li><a class="nounderline abstract_t">Lehmann K, Ritz E. Angiotensin-converting enzyme inhibitors may cause renal dysfunction in patients on long-term lithium treatment. Am J Kidney Dis 1995; 25:82.</a></li><li><a class="nounderline abstract_t">LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81:1721.</a></li><li><a class="nounderline abstract_t">Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65 Suppl 18:27.</a></li><li><a class="nounderline abstract_t">Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation 2014; 130:546.</a></li><li><a class="nounderline abstract_t">Jackson JG, Diaz FJ, Lopez L, de Leon J. A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults. Bipolar Disord 2015; 17:575.</a></li><li><a class="nounderline abstract_t">Jamal A, Homa DM, O'Connor E, et al. Current cigarette smoking among adults - United States, 2005-2014. MMWR Morb Mortal Wkly Rep 2015; 64:1233.</a></li><li><a class="nounderline abstract_t">de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005; 76:135.</a></li><li><a class="nounderline abstract_t">Freedman R. α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia. Annu Rev Med 2014; 65:245.</a></li><li class="breakAll">https://www.cdc.gov/mmwr/volumes/65/wr/mm6544a2.htm (Accessed on May 10, 2018).</li><li><a class="nounderline abstract_t">Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry 2010; 23:112.</a></li><li><a class="nounderline abstract_t">Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013; :CD007253.</a></li><li><a class="nounderline abstract_t">Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007; 27:380.</a></li><li><a class="nounderline abstract_t">West R, Evins AE, Benowitz NL, et al. Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction 2018; 113:1507.</a></li><li><a class="nounderline abstract_t">Evins AE, Cather C, Laffer A. Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices. Harv Rev Psychiatry 2015; 23:90.</a></li><li><a class="nounderline abstract_t">van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev 2013; :CD006102.</a></li><li><a class="nounderline abstract_t">Williams JM, Anthenelli RM, Morris CD, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012; 73:654.</a></li><li><a class="nounderline abstract_t">Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387:2507.</a></li><li><a class="nounderline abstract_t">Chengappa KN, Perkins KA, Brar JS, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014; 75:765.</a></li><li><a class="nounderline abstract_t">Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 2014; 311:145.</a></li><li><a class="nounderline abstract_t">Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 2013; 159:390.</a></li><li><a class="nounderline abstract_t">Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry 2013; 170:1460.</a></li><li><a class="nounderline abstract_t">Thomas KH, Martin RM, Knipe DW, et al. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ 2015; 350:h1109.</a></li><li class="breakAll">https://www.fda.gov/Drugs/DrugSafety/ucm532221.htm (Accessed on July 19, 2017).</li><li><a class="nounderline abstract_t">George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000; 157:1835.</a></li></ol></div><div id="topicVersionRevision">Topic 105342 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16338246" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Schizophrenia and increased risks of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19595447" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313570" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Excess early mortality in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923917" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mortality in schizophrenia: a measurable clinical endpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10978869" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mortality and causes of death in schizophrenia in Stockholm county, Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040880" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Causes of the excess mortality of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23517118" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A behavioral weight-loss intervention in persons with serious mental illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16187768" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15003083" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Consensus development conference on antipsychotic drugs and obesity and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22009159" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22207632" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361837" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262678" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38161305" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Psychotropic Drug-Related Weight Gain and Its Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19653979" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768610" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14624190" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32791894" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36946605" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23846733" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18245179" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27337425" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16062095" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12805393" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636967" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20459883" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28601891" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37753625" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antipsychotics and the risk of diabetes and death among adults with serious mental illnesses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26043321" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21216567" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22893011" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16344421" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Disparities in diabetes care: impact of mental illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17412857" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Quality of diabetes care among adults with serious mental illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978096" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16842977" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A lifestyle intervention for older schizophrenia patients with diabetes mellitus: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20434886" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20434886" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: a 6-month follow-up analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27631964" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Randomized Trial of an Integrated Behavioral Health Home: The Health Outcomes Management and Evaluation (HOME) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24171916" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21379357" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23437800" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16884895" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26221050" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7810540" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Angiotensin-converting enzyme inhibitors may cause renal dysfunction in patients on long-term lithium treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2184951" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15600382" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dyslipidemia and atypical antipsychotic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015340" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26238269" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26562061" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Current cigarette smoking among adults - United States, 2005-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15949648" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24111888" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24111888" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20051860" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Why do patients with schizophrenia smoke?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450574" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Interventions for smoking cessation and reduction in individuals with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632223" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508470" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25747922" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23963776" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Smoking cessation interventions for smokers with current or past depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22697191" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116918" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006684" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399553" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24042367" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24030388" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Varenicline, smoking cessation, and neuropsychiatric adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25767129" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25767129" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11058482" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
